. 2021 Sep 16;6(38):24981–25001. doi: 10.1021/acsomega.1c04016

Table 2. In Vitro Antifungal Activities of the Target Compounds against Seven FLC-Resistant Candida Isolates (PMIC₉₀, μg/mL).

	*resistant Candida* isolates**^a
compd	strain R₁	strain R₂	strain R₃	strain R₄	strain R₅	strain R₆	strain R₇
8b	0.25	0.5	2	1	2	2	1
8c	0.5	1	2	2	2	2	2
FLC	>64	>64	>64	>64	>64	>64	>64

FLC-resistant clinical Candida isolate (R₁–R₆: C. albicans; R₇: C. glabrata) from archived isolates (Refs (27−29)). R₁–R₇ strains were provided by the Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Table 2. In Vitro Antifungal Activities of the Target Compounds against Seven FLC-Resistant Candida Isolates (PMIC90, μg/mL).

Table 2. In Vitro Antifungal Activities of the Target Compounds against Seven FLC-Resistant Candida Isolates (PMIC₉₀, μg/mL).